SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility as investors debate the impact of aggressive AI infrastructure spending and cost-cutting measures, with the community actively analyzing whether the stock's recent sharp decline represents a capitulation bottom or a deeper structural issue. Despite the sell-off, many market participants are closely monitoring support levels, debating the long-term potential of its OCI backlog versus concerns over debt and sector-wide weakness in software.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is currently a focal point for investors due to its critical role in providing rapid, decentralized power solutions for AI data centers amid a broader sector trend of power infrastructure bottlenecks. Market participants are actively debating the stock's high volatility and valuation, with community sentiment split between bullish enthusiasm for its long-term growth potential and caution regarding potential overextension and sensitivity to broader macroeconomic pressures.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing intense momentum as the community reacts to its upcoming inclusion in the Nasdaq-100 index, with many traders closely monitoring a potential short squeeze and high-volume institutional buying. Investors are fiercely debating whether the stock's parabolic ascentfueled by critical AI hardware demandis a sustainable re-rating or a classic blow-off top.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is experiencing a significant surge in investor attention following the FDA's decision to grant full approval for FILSPARI in IgA nephropathy, marking a major milestone for the company. The community is actively debating the stock's future, with many weighing the positive momentum of this regulatory win against potential volatility and long-term valuation concerns.

Maulcoin

Maulcoin is trending as a dedicated community of 'Maulers' actively promotes the project across social platforms, focusing on organic growth and the goal of erasing zeros to reach higher market cap milestones. Investors are engaged in spirited discussions about building diamond-hand discipline, challenging each other to buy on dips, and sharing the collective vision for the project's long-term potential as a top-tier meme coin.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is surging following an announcement that it will acquire DustPhotonics for $750 million to bolster its AI-driven silicon photonics capabilities. The community is actively discussing this strategic expansion as a major growth catalyst, with investors debating the company's valuation and its potential to capture significant market share in the rapidly evolving data center connectivity sector.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors react to speculation surrounding potential leadership changes at the FDA's CBER, which could shift the regulatory environment for its lead drug candidate, Deramiocel. The community is actively discussing the possibility of early approval and the potential for a significant valuation re-rating, viewing recent stock volatility as institutional positioning ahead of a major catalyst.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing a massive, volatile short squeeze that has drawn comparisons to previous meme-stock phenomena, leaving the community sharply divided between those riding the parabolic momentum and those betting on an inevitable, fundamental-driven collapse. Investors are closely monitoring record-high short interest and limited share availability, which continue to fuel extreme price swings and intense debate over potential share dilution or regulatory intervention.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave Inc. is experiencing intense market interest driven by back-to-back major partnerships with Meta and Anthropic, which have significantly bolstered the company's AI infrastructure narrative. While community sentiment remains polarized between bullish investors cheering the massive contract expansion and skeptics raising concerns over high debt loads and frequent capital raises, the stock is seeing significant institutional options flow and volatility as traders debate whether these deals mark a structural shift in AI cloud competition.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest a string of positive analyst notes and the FDA's recent award of a National Priority Voucher for their pancreatic cancer drug, daraxonrasib. The community is actively debating the company's premium valuation and competitive positioning against peers like Verastem and ImmunityBio as the firm advances its pivotal Phase 3 RASolute trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Vanguard Extended Market Index Fund ETF Shares (VXF) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Plus has appointed Eric J. Daniels as its chief development officer, effective April 20.</li><li>The company also received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma and ependymoma.</li></ul>Shares of Plus Therapeutics Inc. (PSTV) rallied 24% on Friday on the heels of the company announcing the appointment of a new chief development officer (CDO) and the U.S. Food and Drug Administration granting its experimental therapy an orphan drug designation.The stock is on track to record its best week since late September if the gains hold.Plus Therapeutics announced a 1-for-25 stock split last month in a bid to meet Nasdaq’s requirements for minimum share price for continued trading on the bourse. The stock began trading on a post-split basis on April 2.Houston, Texas-headquartered Plus has since announced that it has appointed Eric J. Daniels as its CDO, effective April 20. Daniels most recently was CDO at Kiora Pharmaceuticals, overseeing the company’s clinical, preclinical, and Chemistry, Manufacturing, and Controls (CMC) activities, Plus said.The company also said earlier this week that the FDA has granted Orphan Drug Designation to its radiotherapeutic REYOBIQ for the treatment of pediatric malignant gliomas, or aggressive brain tumors.Orphan Drug Designation is granted by the FDA to investigational therapies intended to treat rare diseases affecting fewer than 200,000 people in the United States. The designation provides several potential benefits including tax credits, fee waivers, and potential market exclusivity.The company also said that it received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma and ependymoma.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PSTV stock stayed within the ‘extremely bullish’ territory over the past 12 months, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed pessimism about the company’s new CDO appointment, noting that Kiora shares slumped over the past year.<stembedurl>https://www.stocktwits.com/andre82/message/649952051</stembedurl>Yet another, however, said that the stock is very undervalued.<stembedurl>https://www.stocktwits.com/RadioIsotope25/message/649951802</stembedurl><a href="https://stocktwits.com/symbol/PSTV">PSTV stock</a> has dropped about 76% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally

Earlier this week, Plus Therapeutics said that the FDA has granted Orphan Drug Designation to its experimental drug REYOBIQ for the treatment of pediatric malignant gliomas. 

Equity

Earlier this week, Plus Therapeutics said that the FDA has granted Orphan Drug Designation to its experimental drug REYOBIQ for the treatment of pediatric malignant gliomas. 


<ul class="summary-bullets"><li>The cash consideration represents a 3% discount to the stock’s closing price on Tuesday.</li><li>The company didn’t elaborate on the value of the CVR but said that it is related to potential future milestones for its Sprix nasal spray.&nbsp;</li><li>The transaction, approved by the board of directors of both companies, is expected to close in the second quarter of 2026.</li></ul>Shares of Assertio Holdings, Inc. (ASRT) fell by over 1% after-hours on Wednesday after the company said that it has entered into an agreement to be acquired by Garda Therapeutics for a total cash consideration of $125.1 million.Under the deal, Garda will pay Assertio shareholders $18 per share in cash and a contingent value right (CVR). The cash consideration represents a 3% discount to the stock’s closing price on Tuesday.The company didn’t elaborate on the value of the CVR but said that it is related to potential future milestones for its Sprix nasal spray.The transaction, approved by the board of directors of both companies, is expected to close in the second quarter of 2026 and is subject to customary closing conditions, the pharmaceutical company said. Assertio’s common stock will no longer be listed for trading on Nasdaq following the closing of the deal, which follows the strategic review process initiated by the company in the first quarter of 2025.<h2 class="st-heading-2">Window Shop Period</h2>Assertio also said on Wednesday that its buyout agreement includes a 20-day “window-shop” period, meaning that the company is free to engage with other parties who may provide superior value in the period.A reduced breakup fee would apply if Assertio’s board terminates its agreement with Garda in favor of a superior bid during the period.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ASRT stock stayed within ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Stocktwits users expressed disappointment over the deal.One user called the deal a ‘robbery.’<stembedurl>https://www.stocktwits.com/TikStockTok/message/649766893</stembedurl>Another user reiterated the prior user’s stance.<stembedurl>https://www.stocktwits.com/Chrissytina/message/649766497</stembedurl><a href="https://stocktwits.com/symbol/ASRT">ASRT stock</a> has gained nearly 130% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-chinese-rival-beat-it-with-first-us-long-haul-electric-truck-delivery/cZJf7VDRIAA">Tesla’s Chinese Rival Beat It With First US Long Haul Electric Truck Delivery — What Does This Mean For The EV Giant?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

ASRT Stock Drops After-Hours On Discounted Buyout Deal — Retail Calls It A ‘Robbery’ 

Under the deal, Garda Therapeutics will pay Assertio shareholders $18 per share in cash and a contingent value right.

<ul class="summary-bullets"><li>Mawson Infrastructure Group shares surged more than 60% to a two-month high after a board overhaul.</li><li>The company appointed a new leadership team, including a new executive chairman, CEO, and COO.</li><li>The changes follow a cooperation agreement with activist investor Endeavor.</li></ul>Shares of Mawson Infrastructure Group (MIGI) surged more than 60% to hit a two-month high in midday trade on Wednesday after the company announced a sweeping overhaul of its board of directors.The company said its reconstituted board will include seven new directors, among them Lisa R. Hough, Daniel J. Morrison, K. Rodger Davis, and Kyle B. Danges. Joshua Kilgore has been appointed executive chairman, while Phil Stanley will take over as chief executive officer, and Cody Smith will serve as chief operating officer.The changes follow a cooperation agreement reached earlier this week with the activist investor group Endeavor. As part of the deal, three directors — Ryan Costello, Kathryn Schellenger, and Steven Soles — stepped down.<h2 class="st-heading-2">What Are Retail Traders Saying About MIGI’s stock?</h2><a href="https://stocktwits.com/symbol/MIGI/">MIGI’s stock</a> rose 63% to an over two-month high of $4.88 in midday trade. The shares were among the top 10 gainers across the stock market and were the top-performing crypto equity on Wednesday. Retail sentiment around the company on Stocktwits trended in ‘extremely bullish’ territory over the past day, with chatter rising to ‘extremely high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_08_133822_png_bf2cf90e15.webp" alt="Screenshot 2026-04-08 133822.png" width="1360" height="140"><figcaption>MIGI retail sentiment and message volume on April 8 as of 1:15 p.m. ET | Source: Stocktwits</figcaption></figure>Many users on the platform were&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.stocktwits.com/jschor88/message/649722946">optimistic</a> about the changes a new board could bring to the company. One user pointed to better alignment between management and shareholders, expressing optimism that the new team could prioritize long-term value creation.<stembedurl>https://www.stocktwits.com/caracicatriz/message/649678156</stembedurl>However, others expressed more caution, questioning whether the leadership transition would translate into meaningful operational improvements or sustained share price support.<stembedurl>https://www.stocktwits.com/milliyen/message/649707709</stembedurl><h2 class="st-heading-2">Activist Agreement Ends Months-Long Dispute</h2>The agreement resolved a months-long dispute between Mawson and Endeavor, which had built a significant stake in the company, reaching roughly 48% by late January through a series of share purchases.Tensions escalated earlier this year after Mawson adopted a shareholder rights plan, commonly known as a “poison pill,” to limit further accumulation. Endeavor subsequently pushed for greater control, including efforts to replace the entire board through a consent solicitation and proposals tied to a potential tender offer and equity financing.The two sides ultimately reached a settlement aimed at stabilizing governance and allowing Mawson to focus on its core operations, including digital infrastructure supporting artificial intelligence (AI), high-performance computing (HPC), and Bitcoin (BTC) mining, where the company operates about 129 megawatts of capacity.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/adam-back-denies-he-s-satoshi-nakamoto-says-its-coincidence/cZJOvwORIqq">Adam Back Denies He’s Satoshi Nakamoto, Says It’s ‘Coincidence And Similar Phrases’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of Bitcoin. (Photo by Andriy Onufriyenko via Getty Images)

MIGI Stock Surges To Two-Month High After Activist-Driven Board Overhaul

Mawson Infrastructure Group was the top-performing crypto-linked equity on Wednesday and among the top 10 gainers in the stock market.

Cryptocurrency

Mawson Infrastructure Group was the top-performing crypto-linked equity on Wednesday and among the top 10 gainers in the stock market.


<ul class="summary-bullets"><li>The investing group highlighted that the effective path to unlocking shareholder value would be for Chegg to undertake a strategic separation of its business units.</li><li>Galloway Capital also disclosed that it has acquired a 5.44% stake in Chegg.</li><li>The group stated that Chegg maintains a strong balance sheet and that it has no credible risk of financial distress.</li></ul>Chegg Inc. (CHGG) shares soared more than 20% in Wednesday’s midday trade after the company disclosed a letter from one of its significant shareholders, Galloway Capital Partners.According to the letter addressed to Chegg CEO Dan Rosensweig, Galloway Capital stated that CHGG’s current price reflects a “substantial disconnect” from intrinsic value.“At present levels, the market appears to be incorrectly pricing the business as though it is in financial distress. The Company maintains a strong balance sheet, is expected to exit the year with net cash and no debt, and, in our view, has no credible risk of financial distress,” Galloway Capital stated in its letter.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CHGG">Chegg</a> trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">Galloway Capital Highlights Path To Unlocking Shareholder Value</h2>The group highlighted that the effective path to unlocking shareholder value would be for Chegg to undertake a strategic separation of its business units.Galloway Capital stated that Chegg’s Skilling segment is generating approximately $72 million in annualized revenue. The group noted that this unit has the potential to grow at a sustained double-digit rate, with an addressable market of about $40 billion.“As a standalone business, we believe it would command a materially higher technology valuation multiple reflective of its growth profile,” Galloway Capital added.It also noted that Chegg’s legacy Academic Services business could generate meaningful cash flow over the coming years, while this is not reflected in the company’s current valuation.“We are encouraged by the Company’s efforts to align its cost structure and invest in areas of future demand, including AI-enabled learning and workforce development,” the group added.<h2 class="st-heading-2">Galloway Capital Discloses Stake In Chegg</h2>Galloway Capital also disclosed that it has acquired a 5.44% stake in Chegg. Bruce Galloway, the group's Chief Investment Officer, stated that Chegg is materially undervalued. “With a more focused strategic structure and continued execution, we see a clear and actionable path to unlocking significant shareholder value,” he added.Galloway Capital stated that it looks forward to engaging with Chegg’s management team and board to explore opportunities to enhance long-term shareholder value.In February 2026, Chegg reported full-year 2025 revenue of $377 million, declining 39% over the prior period. Its net loss for the period was $103 million, compared with a net loss of $837 million in 2024.<a href="https://stocktwits.com/symbol/CHGG">CHGG stock</a> is down 9% year-to-date, but up 73% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 37% over the past 12 months, while the Vanguard Small-Cap Index Fund ETF (VB) is up 41%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-microsoft-down-current-status-april-2026/cZJfcpWRIAg">Is Microsoft Down? Downdetector Reports Issues With Microsoft 365, Teams, Outlook, Azure And Other Services</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A laptop keyboard and Chegg logo displayed on a phone screen are seen in this illustration photo taken in Krakow, Poland on May 4, 2023. 

CHGG Stock Soars Following Galloway Capital’s Letter To Chegg CEO — What Did It Say?

Galloway Capital stated that based on its analysis, Chegg’s current share price reflects a “substantial disconnect” from intrinsic value.

<ul class="summary-bullets"><li>iBio stated that it expects to dose the first participant in Australia with IBIO-600 in the second quarter.</li><li>The company’s previously announced pre-clinical studies showed that IBIO-600 demonstrated a pharmacologic activity and an extended half-life of 40–52 days following a single administration in non-human primates.</li><li>iBio stated that it also observed an increase of over 5.1% in lean muscle mass during its pre-clinical studies.</li></ul>iBio Inc. (IBIO) shares gained nearly 10% in Wednesday’s pre-market trade after the company announced that its muscle-preserving drug has received approval for the first in-human trial in Australia.iBio stated that IBIO-600 has been approved by Australia’s Therapeutic Goods Administration (TGA) to initiate a Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in overweight and obese adult participants.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBIO">iBio</a> trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">First Participant Expected To Be Dosed In Q2</h2>iBio stated that it expects to dose the first participant in Australia with IBIO-600 in the second quarter (Q2).“While GLP-1 therapies have transformed the treatment landscape, significant gaps remain, particularly around the loss of muscle mass. We believe IBIO-600 has the potential to address this unmet need,” said iBio CEO Martin Brenner.iBio’s previously announced pre-clinical studies showed that IBIO-600 demonstrated a pharmacologic activity and an extended half-life of 40–52 days following a single administration in non-human primates.The company also observed an increase of over 5.1% in lean muscle mass during its pre-clinical studies.“These findings, observed alongside reductions in fat mass and durable effects over time, support the advancement of IBIO-600 into clinical development,” the company added.<h2 class="st-heading-2">What Does IBIO-600 Do?</h2>IBIO-600 is a long-acting monoclonal antibody that targets myostatin and GDF11, which are proteins that inhibit skeletal muscle growth.It is designed to help preserve lean muscle and improve body composition in patients with obesity. iBio stated that it has the potential to be used alongside GLP-1 treatments to counter muscle loss during weight reduction.<a href="https://stocktwits.com/symbol/IBIO">IBIO stock</a> is up 9% year-to-date and 40% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 31% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 36% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dal-stock-soars-delta-air-lines-q1-results-beat-expectations/cZJODXcRIqr">DAL Stock Soars As Delta Air Lines Beats Q1 Expectations, CEO Says ‘Demand Remains Strong’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia

iBio stated that IBIO-600 has been approved by Australia’s Therapeutic Goods Administration to initiate a Phase 1 study in overweight and obese adult participants.

<ul class="summary-bullets"><li>Hyperscale Data announced on Tuesday that its restricted cash and Bitcoin holdings had reached $102 million, close to 190% of the company’s market cap.</li><li>The company's Bitcoin treasury stood at roughly $44 million, while cash and restricted cash totaled $58 million.</li><li>Chairman Milton “Todd” Ault III criticized the market for overlooking balance sheet strength and reaffirmed plans to continue adding Bitcoin while expanding artificial intelligence infrastructure.</li></ul>Hyperscale Data Inc (GPUS) reported on Tuesday that its total cash, restricted cash, and Bitcoin (BTC) holdings had reached about $102 million, which was almost 190% of its current market capitalization.&nbsp;According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/hyperscale-datas-102-million-in-cash-restricted-cash-and-bitcoin-holdings-significantly-exceed-current-market-capitalization-of-company-302735368.html">press release</a>, Hyperscale Data’s Bitcoin treasury was valued at about $44 million, and its cash and restricted cash at about $58 million. The total value of these assets was almost 189.92% of the company's current market capitalization, which is about $55 million.Chairman Milton "Todd" Ault III said the market wasn't fully reflecting the value of those assets on the company's balance sheet. He also reiterated that he planned to continue buying Bitcoin and to grow the company's artificial intelligence (AI) data center operations.&nbsp;<a href="https://stocktwits.com/symbol/GPUS">Hyperscale’s stock</a> was down 0.6% on morning trade. On Stocktwits, the retail sentiment around GPUS remained in the ‘bullish’ zone, while chatter remained at ‘high’ levels over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_07_at_11_32_13_AM_png_bf80b632a5.webp" alt="Screenshot 2026-04-07 at 11.32.13 AM.png" width="944" height="104"><figcaption>GPUS retail sentiment and message volume on April 7 as of 11:33 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Crypto Firms Expand Into AI And Data Center Infrastructure</h2>Hyperscale Data has increasingly tied its strategy to both digital assets and the infrastructure needed for AI.&nbsp;Last month, the company said that it was an "AI data center company anchored by Bitcoin." It also said that its subsidiary, Alliance Cloud Services, had entered an agreement to acquire about 48.5 acres of land to expand its Michigan campus to meet the growing demand for AI and high-performance computing.&nbsp;Other big crypto-related companies have made similar moves in the past few months. In December last year, Hut 8 Corp (HUT)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hut8-shares-surged-more-than-doubled-in-six-months/cmxuTYwR4R1">announced</a> it was building AI data center infrastructure in Louisiana for Anthropic,&nbsp;one of&nbsp;the world's largest AI companies.MARA Holdings Inc. (MARA) also said that it was building data center infrastructure for power generation projects in Texas. These changes came as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bitcoin-supply-tugofwar-riot-mara-sell-strategy-buying/cZJJr55RIpj">many crypto mining</a> businesses are moving to integrate with data centers and computing infrastructure, especially as&nbsp;<a href="https://stocktwits.com/coins/bitcoin">Bitcoin’s price</a> keeps retesting $70,000.GPUS’ stock is down over 21% year-to-date and has fallen 93% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bit-digital-cuts-eth-staking-to-boost-treasury-flexibility-holds-322-million-in-wyfi-shares/cZJJutJRIpq">Bit Digital Cuts ETH Staking To Boost Treasury Flexibility, Holds $322 Million In WYFI Shares</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AI data centers are seen on show at the Mobile World. (Photo by Davide Bonaldo/SOPA Images/LightRocket via Getty Images)

Hyperscale Data Reports $102 Million In Assets, Nearly Double Its Market Cap

Many top crypto-related companies have recently transitioned into artificial intelligence and data center infrastructure.

<ul class="summary-bullets"><li>The SBIR Phase I contract bagged by the Cemtrex subsidiary is designed by the U.S. Department of Defense for small businesses that demonstrate solutions to specific military requirements.</li><li>Cemtrex stated in a previous update that Invocon’s acquisition is expected to contribute $6 million to $7 million in revenue over the next 12 months.</li><li>The company announced that Advanced Industrial Services, another subsidiary of Cemtrex, bagged a $1.2 million contract in March.</li></ul>Cemtrex Inc. (CETX) more than doubled in Tuesday’s opening trade before paring some of the gains after the company announced that its subsidiary has been awarded a contract by the U.S. Navy.Cemtrex stated that its subsidiary, Invocon, Inc., has been chosen under Phase 1 of the U.S. Navy’s Small Business Innovation Research (SBIR) to work on the Naval Sea Systems Command’s (NAVSEA) Modular Mine Warfare Components program.<a href="https://stocktwits.com/symbol/CETX">Cemtrex shares</a> were up nearly 65% in Tuesday morning’s trade after soaring more than 102% earlier in the opening session. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">Cemtrex CEO Says Contract Award Validates Invocon’s Technical Depth</h2>Cemtrex CEO Saagar Govil stated that the contract award to Invocon validates the subsidiary’s technical depth. Acquired by Cemtrex in January 2026, Invocon is an aerospace and defense engineering firm that specializes in electronics, energetics, power systems, and precision instrumentation for defense and commercial launch customers.“We are pleased to expand Invocon's relationship with NAVSEA and look forward to contributing to U.S. naval capability,” Govil added.SBIR Phase I contracts are designed by the U.S. Department of Defense for small businesses that demonstrate solutions for specific requirements of the military.Cemtrex stated in a previous update that Invocon’s acquisition is expected to contribute $6 million to $7 million in revenue over the next 12 months.<h2 class="st-heading-2">Another Cemtrex Subsidiary Wins $1.2M Contract</h2>Cemtrex announced that its subsidiary, Advanced Industrial Services (AIS), bagged a $1.2 million contract in March.Cemtrex stated that AIS will assist with planning, layout, unloading, installation, and commissioning of production equipment for a large national general contractor.The company added that the project will be executed in multiple phases and is expected to run from the first quarter (Q1) of 2026 through Q1 of 2027.<a href="https://stocktwits.com/symbol/CETX">CETX stock</a> is down 49% year-to-date and 93% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 36% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-fall-ongoing-us-strikes-iran-trump-tuesday-deadline/cZJJpRQRIpL">Dow Futures Fall Over 200 Points Amid Ongoing US Strikes Against Iran, While Trump’s Tuesday Deadline Draws Closer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

CETX Stock More Than Doubles As Cemtrex Subsidiary Bags US Navy Contract

Cemtrex stated that its subsidiary, Invocon, has been chosen under Phase 1 of the U.S. Navy’s Small Business Innovation Research program.

<ul class="summary-bullets"><li>Artelo CEO Gregory D. Gorgas on Tuesday stated that the interim data in the Phase 2 trial of ART27.13 is encouraging.</li><li>Artelo added that ART27.13 is currently under investigation as an orally administered agent for the treatment of glaucoma in an externally funded Phase 2 study.</li><li>The company is also developing ART27.13 as a potential companion therapy to preserve muscle in patients undertaking GLP-1 treatment.</li></ul>Artelo Biosciences Inc. (ARTL) shares soared more than 21% in Tuesday’s pre-market trade&nbsp;before losing most of the gains to hover about 4% higher in the day’s opening trade after the company announced that it has regained compliance with Nasdaq’s listing requirements.Artelo stated that the Nasdaq sent a letter confirming the company is in compliance with the exchange’s rule requiring a minimum of $2.5 million in stockholders’ equity and another rule requiring an annual shareholders’ meeting.The company stated that, in accordance with Nasdaq’s listing rules, Artelo will be subject to a mandatory panel monitor for a period of one year from the date of this letter.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Artelo CEO Says ART27.13 Interim Data Is Encouraging</h2>Artelo CEO Gregory D. Gorgas stated on Tuesday that the interim data from the Phase 2 trial of ART27.13 is encouraging.“With this matter behind us, we remain focused on disciplined execution across our portfolio, including progressing potential partnership negotiations with ART27.13 boosted by the encouraging Phase 2 CAReS interim data suggesting its potential for mitigating or reversing the effects of cancer anorexia-cachexia syndrome,” he said.Artelo added that ART27.13 is currently under investigation as an orally administered agent for the treatment of glaucoma in an externally funded Phase 2 study.<h2 class="st-heading-2">Artelo Expands ART27.13’s Development</h2>The company announced last month that it had expanded development of ART27.13 as a potential companion therapy to preserve muscle in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist therapy.Artelo cited observations among patients with cancer anorexia and cachexia showing improvements in lean body mass and physical activity during ART27.13’s Phase 2 trial.The company also closed an $11 million private placement of 3.2 million shares last week, which it intends to use toward the repayment of certain bridge debt and to meet other working capital requirements.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 84% year-to-date, but down 58% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-fall-ongoing-us-strikes-iran-trump-tuesday-deadline/cZJJpRQRIpL">Dow Futures Fall Over 200 Points Amid Ongoing US Strikes Against Iran, While Trump’s Tuesday Deadline Draws Closer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Artelo Biosciences logo is seen displayed on a smartphone screen.

Why Is ARTL Stock Soaring Today?

Artelo stated that the Nasdaq sent a letter confirming the company is in compliance with the exchange’s rule requiring a minimum of $2.5 million in stockholders’ equity and another rule requiring an annual shareholders’ meeting.

<ul class="summary-bullets"><li>CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows.</li><li>Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.&nbsp;</li><li>Processa develops drugs for life-threatening and life-compromising chronic diseases.</li></ul>Shares of Processa Pharmaceuticals, Inc. (PCSA) closed up 6% and edged up 10% after hours on Thursday after several insiders at the company, including the CEO, made share purchases.According to filings made with the Securities and Exchange Commission, several insiders including Director Baluch Khoso, Chief Development Officer Bigora Sian, Chief Administrative Officer Guy Wendy, Chief Business Strategy Officer Lin Patrick, Chief Executive Officer Ng George K, Director Pannu Geraldine, Chief Financial Officer Skibsted Russell, President of Research &amp; Development Young David all bought shares of the company at a price of about $2.535 on the last day of March.CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows. Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.<h2 class="st-heading-2">About Processa</h2>Processa develops drugs for life-threatening and life-compromising chronic diseases. Its pipeline includes NGC-Cap and NGC-Iri for the treatment of certain cancers, PCS12852 for gastroparesis and constipation disorders and PCS499 for primary glomerular diseases. While the company has completed early-to-mid stage studies for PCS12852 and PCS499, mid-stage trials are in process for NGC-Cap. NGC-Iri, meanwhile, is still in preclinical stages.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PCSA stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.“Nice to see the little token insider purchases apparent "ploy" working just as designed. Predictable, like death and taxes,” a Stocktwits user wrote.<stembedurl>https://www.stocktwits.com/Jwa68/message/649316897</stembedurl>Another voiced optimism for the stock rallying up to $20.<stembedurl>https://www.stocktwits.com/Shallu/message/649328642</stembedurl><a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> has lost nearly 63% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lpcn-stock-crashes-heres-why/cZ7x6c9RI88">LPCN Stock Crashes 78%— Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PCSA Stock Rallies 10% After Hours— Here’s Why

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 

Vanguard Index Funds - Vanguard Extended Market Index ETF

Start of a real move higher

Dead cat - we retest the lows

Show me the results

Software is bouncing hard today. Is this the start of a sustained recovery or just a dead cat bounce before we retest the lows?

Current Price	$217.85
Prev Close	$214.00
Open	$213.34
Dividend Yield	N/A
50-Day Moving Average	$211.98
Beta	N/A
Avg. Volume	598,763.65
PE Ratio	N/A

52-Week High	$223.64
52-Week Low	$156.39
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

VXF
Vanguard Extended Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VXF News

VXFVanguard Extended Market ETF